Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C18ORF25 siRNA
- Development stage
- Preclinical
- Lead developer
- Beijing Hospital
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraosseous
01
Overview
C18ORF25 siRNA is a small interfering RNA (siRNA) therapeutic candidate designed to silence the expression of the C18ORF25 gene. Research presented at the ADA 2025 meeting indicates that C18ORF25 acts as a regulator of glucose metabolism and an inhibitor of the canonical Wnt/β-catenin signaling pathway in bone tissue. By knocking down C18ORF25, the siRNA promotes metabolic reprogramming—specifically increasing glycolysis and oxidative phosphorylation—which in turn drives osteogenic differentiation of osteoblasts. In preclinical rat models, local intraosseous injection of C18ORF25 siRNA was shown to enhance bone turnover, mass, and strength, suggesting its potential as a therapeutic strategy for metabolic bone diseases such as osteoporosis.
- Other names
- siRNA targeting C18ORF25C18orf25-siRNAC-18orf25-siRNAC 18orf25-siRNA
Beyond the preview
Go deeper on C18ORF25 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C18ORF25 siRNA.